Anzeige
Mehr »
Freitag, 19.12.2025 - Börsentäglich über 12.000 News
Breaking News: Übernahme von Weltraum-Technologie ins Portfolio?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CM5J | ISIN: CA71716H1082 | Ticker-Symbol: NCC0
Frankfurt
18.12.25 | 08:03
0,055 Euro
-5,50 % -0,003
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHARMATHER HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
PHARMATHER HOLDINGS LTD 5-Tage-Chart

Aktuelle News zur PHARMATHER Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.12.Pharmather Holdings Ltd: Pharmather closes sale of ketamine ANDA2
02.12.PharmaTher Holdings Ltd.: PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise191Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the...
► Artikel lesen
17.11.PharmaTher Holdings Ltd.: PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program212Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking...
► Artikel lesen
07.11.XFRA NEW INSTRUMENTS AVAILABLE ON 07.11.2025384The following instruments on XETRA do have their first trading 07.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 07.11.2025 Aktien 1 NO0013683821 Appear ASA 2 US30209R1068...
► Artikel lesen
17.10.PharmaTher Holdings Ltd.: PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale418Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the...
► Artikel lesen
17.10.Pharmather Holdings Ltd: Pharmather preparing phase 3 FDA package for ketamine2
16.10.PharmaTher Holdings Ltd.: PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease176Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the...
► Artikel lesen
15.10.Pharmather Holdings Ltd: Pharmather touts "discovery platform" KetAImine3
PHARMATHER Aktie jetzt für 0€ handeln
15.10.PharmaTher Holdings Ltd.: PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings178Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the...
► Artikel lesen
09.10.Pharmather Holdings Ltd: Pharmather talks ketamine as Parkinson's treatment2
08.10.PharmaTher Holdings Ltd.: PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease204Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and timeFDA-reviewed CMC package validated through prior...
► Artikel lesen
02.10.Pharmather Holdings Ltd: Pharmather clarifies sale of one generic ketamine asset1
02.10.PharmaTher Holdings Ltd.: PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy199TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical...
► Artikel lesen
02.10.Pharmather Holdings Ltd: Pharmather signs definitive deal to sell ketamine ANDA1
01.10.PharmaTher announces sale of Ketamine ANDA1
01.10.PharmaTher Holdings Ltd.: PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments114TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical...
► Artikel lesen
27.08.Pharmather Holdings Ltd: Pharmather Holdings advances KETARx after FDA approval4
27.08.PharmaTher Holdings Ltd.: PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx), Aligned with FDA's CNPV National Priority Initiative256Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the...
► Artikel lesen
26.08.Pharmather Holdings Ltd: Pharmather Holdings hoping for big things from KETARx1
15.08.Pharmather Holdings Ltd: Pharmather CEO issues letter after KETARx FDA approval2
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1